USSTOCK.TODAY
Regular Market
Log in Sign up

OpenAI acquires AI startup Orchestra Bio to support drug development

Investing.com +1 ·

OBIO
OBIO Orchestra BioMed Holdings Inc
$5.82 +3.01%
View chart & analysis →
  1. 1OpenAI has acquired Orchestra Bio, a startup building AI agents to assist pharmaceutical companies with drug development management.
  2. 2OpenAI hopes to use AI to shorten the 10 to 15 years typically required to develop new drugs.
  3. 3Anthropic entered the life sciences sector in April by acquiring Coefficient Bio for approximately 400 million dollars.

So what's the key point?

OpenAI bought a company that helps with the process of making medicine. They aim to use artificial intelligence to reduce the time it takes to develop drugs.

Source Investing.com +1 · View original ↗

Related 3-line summaries

Genuine Parts to Pursue Corporate Spin-off in Early 2027 and Records $6.5 Billion in Revenue The Motley Fool +2 · 12h agoMeta's Advertising Revenue Resilience and Alphabet's Cloud Expansion The Motley Fool +1 · 12h agoNetflix projects Q4 revenue and profit to miss estimates Proactive +5 · 12h ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news